Drug Trial Radar · NCT01649245
Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C
Last checked: Nov 20, 2026Latest source record: Jan 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
5,000
Planned (sponsor's estimate)
Start
Aug 2012
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- MinaPharm PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a multi-center study of the efficacy of a new Pegylated Hansenula-derived recombinant interferon α 2a (Reiferon Retard® 160 µg once weekly in combination with ribavirin in treatment of Egyptian patients with chronic hepatitis C for 48 weeks. hepatitis C virus (HCV) viral load will be assessed during therapy at weeks 12, 24 and end of treatment, as well as 24 weeks after therapy is completed.
Conditions
- Chronic Hepatitis C
Interventions
Reiferon retardDrug
Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Virologic Response (SVR)Time frame: Assessed 24 weeks after the end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Liver Institute
Shebin El-Kom, Monufia Governorate, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.